Taconic Biosciences Secures Exclusive CRISPR Licensing Deal with Helmholtz Munich

Taconic Biosciences has entered an exclusive license agreement with Helmholtz Munich, a top biomedical research center in Germany, to enhance preclinical research capabilities.

Through this partnership, Taconic gains exclusive rights to a patented CRISPR-based gene editing technology developed at Helmholtz Munich—advancing the creation of genetically modified animal models for biomedical research.

Learn more